SCHEMBL3688075

SCHEMBL3688075

CN1CCN(c2cccc3c2C=Nc2ccccc2N3)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.51
DRD4 P21917 4/20 0.51
CHRM1 P11229 8/20 0.44
DRD3 P35462 4/20 0.44
ADRA2C P18825 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HTR3E A5X5Y0 2/20 0.42
HTR3B O95264 2/20 0.42
ABCB11 O95342 2/20 0.42
LMNA P02545 2/20 0.42
ADRB2 P07550 2/20 0.42
CHRM2 P08172 2/20 0.42
CHRM4 P08173 2/20 0.42
HTR1A P08908 2/20 0.42
CHRM5 P08912 2/20 0.42
ADRA2A P08913 2/20 0.42
ADRA2B P18089 2/20 0.42
CHRM3 P20309 2/20 0.42
DRD1 P21728 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18639880 0.86 CHRNA7 (0.40) DRD2DRD4CHRM1DRD3MEN1
SCHEMBL3277971 0.85 DRD2 (0.56) DRD2DRD4CHRM1DRD3ADRA2C
SCHEMBL30416496 0.85 DRD2 (0.56) DRD2DRD4CHRM1DRD3ADRA2C
SCHEMBL6029951 0.85 HTR1A (0.44) DRD2CHRM1DRD3HTR3EHTR3B
Hydrochloric Acid SCHEMBL5445211 0.84 DRD2 (0.55) DRD2DRD4CHRM1DRD3ADRA2C
SCHEMBL9406688 0.81 DRD2 (0.48) DRD2DRD4CHRM1DRD3ADRA2C
SCHEMBL23234145 0.80 DRD2 (0.41) DRD2DRD4CHRM1DRD3ADRA2C
SCHEMBL5445017 0.80 CHRM1 (0.49) DRD2DRD4CHRM1DRD3ADRA2C
SCHEMBL3685628 0.78 HRH4 (0.51) DRD2DRD4CHRM1DRD3ADRA2C
Hydrochloric Acid SCHEMBL5606159 0.77 HRH4 (0.50) DRD2DRD4CHRM1DRD3ADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010048264-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2010-04-29 WO disclosed
EP-1691744-A4 METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS COMBINATORX INC (US) 2007-12-26 EP disclosed
WO-2007146012-A1 TREATMENT OF PERIODONTAL DISEASE ASSOCIATED WITH INCREASED C-REACTIVE PROTEIN LEVELS COMBINATORX, INCORPORATED (US) 2007-12-21 WO disclosed
EP-1691744-A2 METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS CombinatoRx, Incorporated (US) 2006-08-23 EP disclosed
WO-2005048927-A2 METHODS AND REAGENTS FOR THE TREATMENT OF INFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2005-06-02 WO disclosed
EP-1100803-A2 PYRROLO 2,1-B] 1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) 2001-05-23 EP disclosed
WO-2000006579-A2 PYRROLO[2,1-B][1,3]BENZOTHIAZEPINES WITH ATYPICAL ANTIPSYCHOTIC ACTIVITY SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2000-02-10 WO disclosed
WO-1996029316-A1 NEW SULFONE ESTER ANALOGUES OF iso-CLOZAPINE AND RELATED STRUCTURES: ATYPICAL NEUROLEPTICS WIKSTROEM HAAKAN (NL) 1996-09-26 WO disclosed